PIRS - The Buzz Show: Pieris Pharmaceuticals (NASDAQ: PIRS) Collaboration with Genentech

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Pieris Pharmaceuticals, Inc. Climbs Following Respiratory and Ophthalmology Collaboration with Genentech ”

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) surged over 21% in premarket trading after the company announced a respiratory and ophthalmology collaboration with Genentech.

The company has entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology.

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies, including AstraZeneca, Seagen, and Servier. Anticalin ® is a registered trademark of Pieris.

For more information, please visit: Pieris Pharmaceuticals, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Pieris Pharmaceuticals (NASDAQ: PIRS) Collaboration with Genentech first appeared on Financial Buzz .

For further details see: